Document is current
Any future updates will be listed below
-
Authors
Hicks, Wayne
Jana, Sirsendu
Kassa, Tigist
Prince, Richard
Cabrales, Pedro
Friedman, Joel
Alayash, Abdu I.
-
Funding
Funding for this research was provided by:
CBER Product Horizon Fund, US FDA/ CBER
National Heart, Lung, and Blood Institute (R01HL159862)
- License Information
-
More Information
Article History
Received: 16 April 2024
Accepted: 10 December 2024
First Online: 28 December 2024
Declarations
:
: Richard Prince is the CEO of Vascarta Inc. Joel Friedman is the scientific founder and CSO of Vascarta Inc. All other authors declare no competing interests.
